Immunohistochemistry (IHC) Market by Product (Antibodies (Type, Clonality), Reagents, Equipment, Kits, Software), Application (Diagnostics (Cancer, Infectious, Autoimmune, Neurological), Research (Drug Development), Forensic) - Global Forecast to 2029
The global immunohistochemistry market is projected to reach USD 5.2 billion by 2029 from USD 3.7 billion in 2024, at a CAGR of 7.2% during the forecast period of 2024 to 2029. Factors propelling the growth of the market are the increased prevalence of cancer cases among the growing geriatric population and the rising application of IHC tests for the diagnosis and management of cancer. Moreover, the development of companion diagnostics (CDx) and its integration with IHC technology for the development of personalized medicine further support the expansion of the market. Application of IHC in supporting drug development and disease management to improve patient outcomes, along with ongoing research collaboration between pharmaceutical companies and academic institutes provide growth opportunities for players in the Immunohistochemistry Market.
“Histological Stain is expected to account for the largest share of by reagents segment.”
In 2023, the histological stains market accounted for the largest share of the reagent subsegment within the product segment. In immunohistochemistry, histological stains are used to visualize and differentiate specific cellular components and structures within tissue samples. Histological stains are also used in multiplex staining also known as multiple staining. In this technique, more than one stains are used to detect multiple targets within a single tissue section. Apart from multiplex staining, histological stains are also used for cancer diagnosis by distinguishing normal and abnormal tissue morphology. These applications are major factors that drive the market for histological stains
“Research applications segment accounted for the second-largest share of the application segment.”
In 2023, research applications accounted for the second-largest share of the application segment of the IHC market. In research, IHC technology is used for anti-tumor drug development and biomarker discovery. It helps researchers to identify the expression of specific proteins and their locations within cells, aiding in the study of cancer and other diseases. For example, IHC is widely used to study the cancer proteome, which helps in finding new drug targets. Automated IHC platforms used in research offer consistent staining across slides, which is essential for reliable results. IHC techniques are also important in developmental studies, like embryological research, where they help visualize key proteins during the embryonic development phase. In stem cell research, IHC is used to monitor differentiation and proliferation markers, providing insights into stem cell behavior. Additionally, in drug testing, IHC helps evaluate the effects of new drugs on specific protein expressions within tissues. These applications highlight the important role of IHC in advancing scientific research and improving the understanding and treatment of various diseases.
“Asia Pacific is the fastest-growing region in the immunohistochemistry market.”
The immunohistochemistry market is segmented into North America, Europe, Asia Pacific, Latin America (LATAM), the Middle East, and Africa. Asia Pacific is the fastest-growing region in terms of CARG during the forecast period. The high growth rate of the region can be attributed to the fast adoption of the latest technologies such as advanced IHC products (like assays and diagnostic kits) in research and clinical applications. This factor, coupled with the increasing geriatric population, rising investments and funding for research activities, increasing disposable income, and developing academic and healthcare infrastructures in the region are key drivers for the high growth rate of the region.
The primary interviews conducted for this report can be categorized as follows:
Research Coverage:
This report provides a detailed picture of the immunohistochemistry market. It aims at estimating the size and future growth potential of the market across different segments such as the product, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall immunohistochemistry market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, challenges, and opportunities.
The report provides insights on the following pointers:
“Histological Stain is expected to account for the largest share of by reagents segment.”
In 2023, the histological stains market accounted for the largest share of the reagent subsegment within the product segment. In immunohistochemistry, histological stains are used to visualize and differentiate specific cellular components and structures within tissue samples. Histological stains are also used in multiplex staining also known as multiple staining. In this technique, more than one stains are used to detect multiple targets within a single tissue section. Apart from multiplex staining, histological stains are also used for cancer diagnosis by distinguishing normal and abnormal tissue morphology. These applications are major factors that drive the market for histological stains
“Research applications segment accounted for the second-largest share of the application segment.”
In 2023, research applications accounted for the second-largest share of the application segment of the IHC market. In research, IHC technology is used for anti-tumor drug development and biomarker discovery. It helps researchers to identify the expression of specific proteins and their locations within cells, aiding in the study of cancer and other diseases. For example, IHC is widely used to study the cancer proteome, which helps in finding new drug targets. Automated IHC platforms used in research offer consistent staining across slides, which is essential for reliable results. IHC techniques are also important in developmental studies, like embryological research, where they help visualize key proteins during the embryonic development phase. In stem cell research, IHC is used to monitor differentiation and proliferation markers, providing insights into stem cell behavior. Additionally, in drug testing, IHC helps evaluate the effects of new drugs on specific protein expressions within tissues. These applications highlight the important role of IHC in advancing scientific research and improving the understanding and treatment of various diseases.
“Asia Pacific is the fastest-growing region in the immunohistochemistry market.”
The immunohistochemistry market is segmented into North America, Europe, Asia Pacific, Latin America (LATAM), the Middle East, and Africa. Asia Pacific is the fastest-growing region in terms of CARG during the forecast period. The high growth rate of the region can be attributed to the fast adoption of the latest technologies such as advanced IHC products (like assays and diagnostic kits) in research and clinical applications. This factor, coupled with the increasing geriatric population, rising investments and funding for research activities, increasing disposable income, and developing academic and healthcare infrastructures in the region are key drivers for the high growth rate of the region.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 70% and Demand Side 30%
- By Designation: Managers - 55%, CXOs - 20%, and Executives - 25%
- By Region: North America -50%, Europe -20%, Asia-Pacific -20%, Latin America- 7%, Middle East and Africa-3%
Research Coverage:
This report provides a detailed picture of the immunohistochemistry market. It aims at estimating the size and future growth potential of the market across different segments such as the product, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall immunohistochemistry market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, challenges, and opportunities.
The report provides insights on the following pointers:
- Analysis of key drivers (Rising Geriatric Population and Increasing Cancer Prevalence, Innovations and advancements in Immunohistochemistry (IHC) Technology, Reimbursement Coverage for Immunohistochemistry (IHC) Tests, Rising Adoption of Digital Pathology), restraint (Adoption of alternative technologies and a high degree of consolidation), opportunities (Rising demand for personalized medicine, Growing adoption of companion diagnostics, Growth opportunities in emerging countries, Integration of artificial intelligence in IHC), Challenges (Stringent regulatory requirements, Lack of Standardization)
- Product Development/Innovation: Detailed insights on newly launched product, and technological assessment of the Immunohistochemistry market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the Immunohistochemistry market across varied regions.
- Market Diversification: Exhaustive information about new, untapped geographies, recent developments, and investments in the Immunohistochemistry market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players like F. Hoffman-La Roche Ltd (Switzerland), Danaher Corporation (US), and Agilent Technologies, Inc. (US) among others in the Immunohistochemistry market. The report also helps stakeholders understand the pulse of the IHC market and provides them with information on key market drivers, restraints, challenges, and opportunities. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the GLP-1 analogues market.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 INCLUSIONS AND EXCLUSIONS
1.4 STUDY SCOPE
1.4.1 SEGMENTS COVERED
1.4.2 YEARS CONSIDERED
1.4.3 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 RESEARCH DESIGN
2.1.2 SECONDARY DATA
2.1.2.1 Secondary data sources
2.1.2.2 Objectives of secondary research
2.1.3 PRIMARY DATA
2.1.3.1 Objectives of primary research
2.2 MARKET SIZE ESTIMATION
2.2.1 REVENUE SHARE ANALYSIS (TOP-DOWN APPROACH)
2.2.2 INSIGHTS FROM PRIMARIES
2.3 MARKET GROWTH FORECAST
2.4 DATA TRIANGULATION
2.5 STUDY ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 IMMUNOHISTOCHEMISTRY MARKET OVERVIEW
4.2 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION AND
COUNTRY (2023)
4.3 IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2024 VS. 2029 (USD MILLION)
4.4 IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2023
4.5 IMMUNOHISTOCHEMISTRY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing prevalence of cancer and rising geriatric population
5.2.1.2 Technological innovations and advancements in immunohistochemistry diagnostics
5.2.1.3 Favorable reimbursement coverage for immunohistochemistry tests
5.2.1.4 Growing focus on digital pathology
5.2.2 RESTRAINTS
5.2.2.1 Adoption of alternative technologies in molecular diagnostics and research
5.2.2.2 Highly consolidated market
5.2.3 OPPORTUNITIES
5.2.3.1 Growing demand for precision/personalized medicines
5.2.3.2 Increasing adoption of companion diagnostics
5.2.3.3 Growth opportunities in emerging economies
5.2.3.4 Integration of AI in immunohistochemistry
5.2.4 CHALLENGES
5.2.4.1 Stringent regulatory requirements for tissue diagnostic instruments and consumables
5.2.4.2 Lack of standardization
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE OF IMMUNOHISTOCHEMISTRY PRODUCTS, 2023
5.4.2 INDICATIVE SELLING PRICE TREND FOR IMMUNOHISTOCHEMISTRY PRODUCTS, 2021–2023
5.4.3 INDICATIVE SELLING PRICE TREND FOR IMMUNOHISTOCHEMISTRY PRODUCTS, BY REGION, 2021–2023
5.5 TECHNOLOGY ANALYSIS
5.5.1 KEY TECHNOLOGIES
5.5.1.1 Automated immunohistochemistry systems
5.5.1.2 Multiplex immunohistochemistry
5.5.2 COMPLEMENTARY TECHNOLOGIES
5.5.2.1 Chromogenic detection
5.5.2.2 Fluorescent detection
5.5.3 ADJACENT TECHNOLOGIES
5.5.3.1 In situ hybridization
5.6 PATENT ANALYSIS
5.6.1 METHODOLOGY
5.6.2 INNOVATION AND PATENT APPLICATIONS
5.6.3 TOP PATENT APPLICANTS
5.7 VALUE CHAIN ANALYSIS
5.7.1 RESEARCH & DEVELOPMENT
5.7.2 MANUFACTURING
5.7.3 LOGISTICS AND POST-SALES
5.8 SUPPLY CHAIN ANALYSIS
5.9 ECOSYSTEM ANALYSIS
5.9.1 ROLE OF RAW MATERIAL SUPPLIERS
5.9.2 ROLE OF PRODUCT PROVIDERS
5.9.3 ROLE OF END USERS
5.9.4 ROLE OF REGULATORY AUTHORITIES
5.10 PORTER’S FIVE FORCES ANALYSIS
5.10.1 INTENSITY OF COMPETITIVE RIVALRY
5.10.2 BARGAINING POWER OF SUPPLIERS
5.10.3 BARGAINING POWER OF BUYERS
5.10.4 THREAT OF SUBSTITUTES
5.10.5 THREAT OF NEW ENTRANTS
5.11 KEY STAKEHOLDERS AND BUYING CRITERIA
5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.11.2 KEY BUYING CRITERIA
5.12 REGULATORY LANDSCAPE
5.12.1 REGULATORY ANALYSIS
5.12.1.1 North America
5.12.1.1.1 US
5.12.1.1.2 Canada
5.12.1.2 Europe
5.12.1.3 Asia Pacific
5.12.1.3.1 Japan
5.12.1.3.2 China
5.12.1.3.3 India
5.12.1.4 Latin America
5.12.1.4.1 Brazil
5.13 KEY CONFERENCES AND EVENTS, 2024–2025
5.14 INVESTMENT AND FUNDING SCENARIO
5.15 IMPACT OF AI/GEN AI ON IMMUNOHISTOCHEMISTRY MARKET
6 IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING
6.1 INTRODUCTION
6.2 ANTIBODIES
6.2.1 IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE
6.2.2 PRIMARY ANTIBODIES
6.2.2.1 Increasing adoption of targeted immunotherapy to drive segment
6.2.3 SECONDARY ANTIBODIES
6.2.3.1 Better signal amplification and easier manufacturing process to fuel segment growth
6.2.4 IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY
6.2.5 MONOCLONAL ANTIBODIES
6.2.5.1 Increased applications in cancer diagnostics to support market growth
6.2.6 POLYCLONAL ANTIBODIES
6.2.6.1 Better sensitivity and higher resistant to changes in antigen conformation to augment segment growth
6.3 REAGENTS
6.3.1 HISTOLOGICAL STAINS
6.3.1.1 Growing focus on cancer diagnostics and developmental research to drive segment
6.3.2 BLOCKING SERA AND REAGENTS
6.3.2.1 Need to prevent non-specific binding and provide accurate outcomes to drive adoption
6.3.3 CHROMOGENIC SUBSTRATES
6.3.3.1 Rapid detection and faster diagnosis to propel segment growth
6.3.4 FIXATION REAGENTS
6.3.4.1 Increased focus on retaining tissue morphology and antigenicity of target molecules to support adoption
6.3.5 DILUENTS
6.3.5.1 Focus on reducing non-specific background staining during immunostaining to aid segment growth
6.3.6 ORGANIC SOLVENTS
6.3.6.1 Need to prevent physical damage in specimens and improve clarity in tissue sample visualization to drive market
6.3.7 PROTEOLYTIC ENZYMES
6.3.7.1 Proteolytic enzymes to improve accessibility of target antibodies
6.3.8 OTHER REAGENTS
6.4 EQUIPMENT
6.4.1 SLIDE-STAINING SYSTEMS
6.4.1.1 Availability of technologically advanced slide-staining systems to fuel segment growth
6.4.2 TISSUE PROCESSING SYSTEMS
6.4.2.1 High equipment cost and need for extensive regulatory compliance to limit market
6.4.3 SLIDE SCANNERS
6.4.3.1 Accurate insights into complexity of tissue interactions and multi-parameter cellular expressions to aid adoption
6.4.4 OTHER EQUIPMENT
6.5 KITS
6.5.1 HUMAN IMMUNOHISTOCHEMISTRY KITS
6.5.1.1 Increasing focus on cancer research to fuel segment growth
6.5.2 ANIMAL IMMUNOHISTOCHEMISTRY KITS
6.5.2.1 Rising focus on drug safety and efficacy in preclinical drug testing to boost segment growth
6.6 SOFTWARE
6.6.1 GROWING FOCUS ON DIGITAL PATHOLOGY FOR MORE ACCURATE DIAGNOSIS TO DRIVE MARKET
7 IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION
7.1 INTRODUCTION
7.2 DIAGNOSTIC APPLICATIONS
7.2.1 CANCER
7.2.1.1 Increasing target population and rising adoption of targeted therapies to propel market growth
7.2.2 INFECTIOUS DISEASES
7.2.2.1 High prevalence of infectious diseases and need for early diagnosis to aid market growth
7.2.3 NEPHROLOGICAL DISEASES
7.2.3.1 Rising prevalence of renal transplant-associated conditions to drive market
7.2.4 AUTOIMMUNE DISEASES
7.2.4.1 Focus on differentiating autoimmune diseases from similar clinical presentations to augment market growth
7.2.5 NEUROLOGICAL DISEASES
7.2.5.1 Increasing global burden of neurological disorders to spur market growth
7.2.6 OTHER DISEASES
7.3 RESEARCH APPLICATIONS
7.3.1 DRUG DEVELOPMENT AND TESTING
7.3.1.1 Need for accurate and objective outcomes in drug testing to augment segment growth
7.3.2 OTHER RESEARCH APPLICATIONS
7.4 FORENSIC APPLICATIONS
7.4.1 INCREASED DEMAND FOR EFFECTIVE DETERMINATION OF PATHOLOGICAL CHANGES TO SUPPORT MARKET GROWTH
8 IMMUNOHISTOCHEMISTRY MARKET, BY END USER
8.1 INTRODUCTION
8.2 HOSPITALS AND DIAGNOSTIC LABORATORIES
8.2.1 LOW COST OF SPECIALTY DIAGNOSTIC TESTS AND HIGH DEMAND FOR PERSONALIZED MEDICINES TO AID MARKET GROWTH
8.3 ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS
8.3.1 GROWING APPLICATION OF IMMUNOHISTOCHEMISTRY TESTS FOR DRUG DEVELOPMENT TO POSITIVELY IMPACT MARKET GROWTH
8.4 OTHER END USERS
9 IMMUNOHISTOCHEMISTRY MARKET, BY REGION
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
9.2.2 US
9.2.2.1 US to dominate North American immunohistochemistry market during forecast period
9.2.3 CANADA
9.2.3.1 High incidence of cancer and increased demand for advanced diagnostics to propel market growth
9.3 EUROPE
9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
9.3.2 GERMANY
9.3.2.1 High investments in life science R&D and favorable reimbursement policies to drive market
9.3.3 UK
9.3.3.1 Rising prevalence of cancer and increasing government funding in health research to augment market growth
9.3.4 FRANCE
9.3.4.1 Increased research in cancer diagnosis and treatment to support market growth
9.3.5 ITALY
9.3.5.1 Advanced health infrastructure and high geriatric population to
fuel market growth
9.3.6 SPAIN
9.3.6.1 Increased demand for personalized medicines to boost adoption
of immunohistochemistry products
9.3.7 REST OF EUROPE
9.4 ASIA PACIFIC
9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
9.4.2 CHINA
9.4.2.1 Increasing focus on advanced cancer diagnostics to spur market growth
9.4.3 JAPAN
9.4.3.1 High geriatric population and increased government healthcare expenditure to support market growth
9.4.4 INDIA
9.4.4.1 Need for high-end pathology and diagnostic services to propel market growth
9.4.5 AUSTRALIA
9.4.5.1 Increased patient population and high demand for quality healthcare to aid market growth
9.4.6 SOUTH KOREA
9.4.6.1 Focus on precision healthcare and personalized medicines to
drive market
9.4.7 REST OF ASIA PACIFIC
9.5 LATIN AMERICA
9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
9.5.2 BRAZIL
9.5.2.1 Increasing incidence of chronic lifestyle diseases and rising investments by private companies to fuel market growth
9.5.3 MEXICO
9.5.3.1 Increasing research initiatives and rising cancer cases to drive market
9.5.4 REST OF LATIN AMERICA
9.6 MIDDLE EAST
9.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
9.6.2 GCC COUNTRIES
9.6.2.1 Saudi Arabia
9.6.2.1.1 Growing cancer burden and increasing focus on research to augment market growth
9.6.2.2 UAE
9.6.2.2.1 Favorable government initiatives and high investments in healthcare infrastructure to fuel market growth
9.6.2.3 Rest of GCC Countries
9.6.3 REST OF MIDDLE EAST
9.7 AFRICA
9.7.1 RAPID RISE IN CANCER CASES AND HIGH HEALTHCARE INVESTMENTS TO DRIVE MARKET
9.7.2 MACROECONOMIC OUTLOOK FOR AFRICA
10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.2 KEY PLAYER STRATEGY/RIGHT TO WIN
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN IMMUNOHISTOCHEMISTRY MARKET
10.3 REVENUE ANALYSIS, 2021–2023
10.4 MARKET SHARE ANALYSIS, 2023
10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
10.5.1 STARS
10.5.2 EMERGING LEADERS
10.5.3 PERVASIVE PLAYERS
10.5.4 PARTICIPANTS
10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
10.5.5.1 Company footprint
10.5.5.2 Offering footprint
10.5.5.3 Application footprint
10.5.5.4 Region footprint
10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
10.6.1 PROGRESSIVE COMPANIES
10.6.2 RESPONSIVE COMPANIES
10.6.3 DYNAMIC COMPANIES
10.6.4 STARTING BLOCKS
10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
10.7 COMPANY VALUATION AND FINANCIAL METRICS
10.7.1 FINANCIAL METRICS
10.7.2 COMPANY VALUATION
10.8 BRAND/PRODUCT COMPARISON
10.9 COMPETITIVE SCENARIO
10.9.1 PRODUCT LAUNCHES AND APPROVALS
10.9.2 DEALS
10.9.3 EXPANSIONS
10.9.4 OTHER DEVELOPMENTS
11 COMPANY PROFILES
11.1 KEY PLAYERS
11.1.1 F. HOFFMANN-LA ROCHE LTD.
11.1.1.1 Business overview
11.1.1.2 Products/Solutions offered
11.1.1.3 Recent developments
11.1.1.3.1 Product launches and approvals
11.1.1.3.2 Deals
11.1.1.4 MnM view
11.1.1.4.1 Key strengths
11.1.1.4.2 Strategic choices
11.1.1.4.3 Weaknesses and competitive threats
11.1.2 DANAHER CORPORATION
11.1.2.1 Business overview
11.1.2.2 Products/Solutions offered
11.1.2.3 Recent developments
11.1.2.3.1 Product launches and approvals
11.1.2.3.2 Deals
11.1.2.4 MnM view
11.1.2.4.1 Key strengths
11.1.2.4.2 Strategic choices
11.1.2.4.3 Weaknesses and competitive threats
11.1.3 AGILENT TECHNOLOGIES, INC.
11.1.3.1 Business overview
11.1.3.2 Products/Solutions offered
11.1.3.3 Recent developments
11.1.3.3.1 Product launches and approvals
11.1.3.3.2 Deals
11.1.3.3.3 Expansions
11.1.3.4 MnM view
11.1.3.4.1 Key strengths
11.1.3.4.2 Strategic choices
11.1.3.4.3 Weaknesses and competitive threats
11.1.4 PHC HOLDINGS CORPORATION
11.1.4.1 Business overview
11.1.4.2 Products/Solutions offered
11.1.4.3 Recent developments
11.1.4.3.1 Deals
11.1.4.3.2 Other developments
11.1.4.4 MnM view
11.1.4.4.1 Key strengths
11.1.4.4.2 Strategic choices
11.1.4.4.3 Weaknesses and competitive threats
11.1.5 THERMO FISHER SCIENTIFIC INC.
11.1.5.1 Business overview
11.1.5.2 Products/Solutions offered
11.1.6 MERCK KGAA
11.1.6.1 Business overview
11.1.6.2 Products/Solutions offered
11.1.7 BIO-RAD LABORATORIES, INC.
11.1.7.1 Business overview
11.1.7.2 Products/Solutions offered
11.1.8 BIO-TECHNE
11.1.8.1 Business overview
11.1.8.2 Products/Solutions offered
11.1.8.3 Recent developments
11.1.8.3.1 Deals
11.1.8.3.2 Expansions
11.1.8.3.3 Other developments
11.1.9 BECTON, DICKINSON AND COMPANY
11.1.9.1 Business overview
11.1.9.2 Products/Solutions offered
11.1.9.3 Recent developments
11.1.9.3.1 Expansions
11.1.10 TAKARA BIO INC.
11.1.10.1 Business overview
11.1.10.2 Products/Solutions offered
11.1.11 ENZO BIOCHEM INC.
11.1.11.1 Business overview
11.1.11.2 Products/Solutions offered
11.1.11.3 Recent developments
11.1.11.3.1 Expansions
11.1.12 SINO BIOLOGICAL, INC.
11.1.12.1 Business overview
11.1.12.2 Products/Solutions offered
11.1.12.3 Recent developments
11.1.12.3.1 Expansions
11.1.13 SAKURA FINETEK JAPAN CO., LTD.
11.1.13.1 Business overview
11.1.13.2 Products/Solutions offered
11.1.13.3 Recent developments
11.1.13.3.1 Product launches
11.1.13.3.2 Deals
11.1.14 CELL SIGNALING TECHNOLOGY, INC.
11.1.14.1 Business overview
11.1.14.2 Products/Solutions offered
11.1.14.3 Recent developments
11.1.14.3.1 Deals
11.1.15 BIO SB
11.1.15.1 Business overview
11.1.15.2 Products/Solutions offered
11.1.15.3 Recent developments
11.1.15.3.1 Product launches
11.1.16 MILTENYI BIOTEC
11.1.16.1 Business overview
11.1.16.2 Products/Solutions offered
11.1.17 ORIGENE TECHNOLOGIES, INC.
11.1.17.1 Business overview
11.1.17.2 Products/Solutions offered
11.2 OTHER PLAYERS
11.2.1 EAGLEBIO
11.2.2 BIOCARE MEDICAL, LLC
11.2.3 ELABSCIENCE BIONOVATION INC.
11.2.4 BIOGENEX
11.2.5 DIAGNOSTIC BIOSYSTEMS INC.
11.2.6 HISTO-LINE LABORATORIES
11.2.7 ROCKLAND IMMUNOCHEMICALS, INC.
11.2.8 CANDOR BIOSCIENCE GMBH
11.2.9 GENEMED BIOTECHNOLOGIES, INC.
12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 CUSTOMIZATION OPTIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
TABLE 1 IMMUNOHISTOCHEMISTRY MARKET: INCLUSIONS AND EXCLUSIONS
TABLE 2 IMMUNOHISTOCHEMISTRY MARKET: IMPACT ANALYSIS
TABLE 3 ESTIMATED NUMBER OF NEW CASES, BY REGION, 2022–2045 (THOUSAND)
TABLE 4 ESTIMATED PERCENTAGE INCREASE IN GERIATRIC POPULATION,
BY REGION, 2022–2050
TABLE 5 CPT CODES FOR IMMUNOHISTOCHEMISTRY PROCEDURES
TABLE 6 MAJOR ACQUISITIONS IN IMMUNOHISTOCHEMISTRY MARKET, 2020–2023
TABLE 7 AVERAGE SELLING PRICE FOR IMMUNOHISTOCHEMISTRY PRODUCTS, 2023
TABLE 8 INDICATIVE SELLING PRICE TREND FOR IMMUNOHISTOCHEMISTRY PRODUCTS, 2021–2023 (USD)
TABLE 9 INDICATIVE SELLING PRICE TREND FOR IMMUNOHISTOCHEMISTRY PRODUCTS,
BY REGION, 2021–2023 (USD)
TABLE 10 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2014–2024
TABLE 11 TOP 20 PATENT OWNERS IN IMMUNOHISTOCHEMISTRY MARKET, 2014–2024
TABLE 12 INDICATIVE LIST OF PATENTS IN IMMUNOHISTOCHEMISTRY MARKET, 2022–2024
TABLE 13 IMMUNOHISTOCHEMISTRY MARKET: ROLE OF RAW MATERIAL SUPPLIERS
TABLE 14 IMMUNOHISTOCHEMISTRY MARKET: ROLE OF PRODUCT PROVIDERS
TABLE 15 IMMUNOHISTOCHEMISTRY MARKET: ROLE OF END USERS
TABLE 16 IMMUNOHISTOCHEMISTRY MARKET: ROLE OF REGULATORY AUTHORITIES
TABLE 17 IMMUNOHISTOCHEMISTRY MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 18 BUYING CRITERIA FOR IMMUNOHISTOCHEMISTRY PRODUCTS, BY END USER
TABLE 19 US: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES
TABLE 20 EUROPE: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES
TABLE 21 JAPAN: CLASSIFICATION OF IN VITRO DIAGNOSTIC REAGENTS
TABLE 22 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
TABLE 23 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
TABLE 24 IMMUNOHISTOCHEMISTRY MARKET: DETAILED LIST OF KEY CONFERENCES
AND EVENTS, JANUARY 2024–DECEMBER 2025
TABLE 25 IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 26 IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGION,
2022–2029 (USD MILLION)
TABLE 27 NORTH AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 28 EUROPE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 29 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 30 LATIN AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 31 MIDDLE EAST: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 32 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 33 IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 34 PRIMARY ANTIBODIES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 35 NORTH AMERICA: PRIMARY ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 36 EUROPE: PRIMARY ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 37 ASIA PACIFIC: PRIMARY ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 38 LATIN AMERICA: PRIMARY ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 39 MIDDLE EAST: PRIMARY ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 40 GCC COUNTRIES: PRIMARY ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 41 SECONDARY ANTIBODIES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 42 NORTH AMERICA: SECONDARY ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 43 EUROPE: SECONDARY ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 44 ASIA PACIFIC: SECONDARY ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 45 LATIN AMERICA: SECONDARY ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 46 MIDDLE EAST: SECONDARY ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 47 GCC COUNTRIES: SECONDARY ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 48 IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,
2022–2029 (USD MILLION)
TABLE 49 MONOCLONAL ANTIBODIES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 50 NORTH AMERICA: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 51 EUROPE: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 52 ASIA PACIFIC: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 53 LATIN AMERICA: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 54 MIDDLE EAST: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 55 GCC COUNTRIES: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 56 POLYCLONAL ANTIBODIES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 57 NORTH AMERICA: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 58 EUROPE: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 59 ASIA PACIFIC: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 60 LATIN AMERICA: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 61 MIDDLE EAST: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 62 GCC COUNTRIES: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 63 IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 64 IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY REGION,
2022–2029 (USD MILLION)
TABLE 65 NORTH AMERICA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 66 EUROPE: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 67 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 68 LATIN AMERICA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 69 MIDDLE EAST: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 70 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 71 HISTOLOGICAL STAINS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 72 NORTH AMERICA: HISTOLOGICAL STAINS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 73 EUROPE: HISTOLOGICAL STAINS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 74 ASIA PACIFIC: HISTOLOGICAL STAINS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 75 LATIN AMERICA: HISTOLOGICAL STAINS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 76 MIDDLE EAST: HISTOLOGICAL STAINS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 77 GCC COUNTRIES: HISTOLOGICAL STAINS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 78 BLOCKING SERA AND REAGENTS MARKET, BY REGION,
2022–2029 (USD MILLION)
TABLE 79 NORTH AMERICA: BLOCKING SERA AND REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 80 EUROPE: BLOCKING SERA AND REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 81 ASIA PACIFIC: BLOCKING SERA AND REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 82 LATIN AMERICA: BLOCKING SERA AND REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 83 MIDDLE EAST: BLOCKING SERA AND REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 84 GCC COUNTRIES: BLOCKING SERA AND REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 85 CHROMOGENIC SUBSTRATES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 86 NORTH AMERICA: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 87 EUROPE: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 88 ASIA PACIFIC: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 89 LATIN AMERICA: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 90 MIDDLE EAST: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 91 GCC COUNTRIES: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 92 FIXATION REAGENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 93 NORTH AMERICA: FIXATION REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 94 EUROPE: FIXATION REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 95 ASIA PACIFIC: FIXATION REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 96 LATIN AMERICA: FIXATION REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 97 MIDDLE EAST: FIXATION REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 98 GCC COUNTRIES: FIXATION REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 99 DILUENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 100 NORTH AMERICA: DILUENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 101 EUROPE: DILUENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 102 ASIA PACIFIC: DILUENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 103 LATIN AMERICA: DILUENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 104 MIDDLE EAST: DILUENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 105 GCC COUNTRIES: DILUENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 106 ORGANIC SOLVENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 107 NORTH AMERICA: ORGANIC SOLVENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 108 EUROPE: ORGANIC SOLVENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 109 ASIA PACIFIC: ORGANIC SOLVENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 110 LATIN AMERICA: ORGANIC SOLVENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 111 MIDDLE EAST: ORGANIC SOLVENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 112 GCC COUNTRIES: ORGANIC SOLVENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 113 PROTEOLYTIC ENZYMES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 114 NORTH AMERICA: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 115 EUROPE: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 116 ASIA PACIFIC: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 117 LATIN AMERICA: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 118 MIDDLE EAST: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 119 GCC COUNTRIES: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 120 OTHER REAGENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 121 NORTH AMERICA: OTHER REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 122 EUROPE: OTHER REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 123 ASIA PACIFIC: OTHER REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 124 LATIN AMERICA: OTHER REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 125 MIDDLE EAST: OTHER REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 126 GCC COUNTRIES: OTHER REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 127 IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 128 IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY REGION,
2022–2029 (USD MILLION)
TABLE 129 NORTH AMERICA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 130 EUROPE: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 131 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 132 LATIN AMERICA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 133 MIDDLE EAST: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 134 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 135 IMMUNOHISTOCHEMISTRY SLIDE-STAINING SYSTEMS MARKET, BY VOLUME, 2022–2029 (UNITS)
TABLE 136 SLIDE-STAINING SYSTEMS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 137 NORTH AMERICA: SLIDE-STAINING SYSTEMS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 138 EUROPE: SLIDE-STAINING SYSTEMS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 139 ASIA PACIFIC: SLIDE-STAINING SYSTEMS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 140 LATIN AMERICA: SLIDE-STAINING SYSTEMS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 141 MIDDLE EAST: SLIDE-STAINING SYSTEMS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 142 GCC COUNTRIES: SLIDE-STAINING SYSTEMS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 143 TISSUE PROCESSING SYSTEMS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 144 NORTH AMERICA: TISSUE PROCESSING SYSTEMS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 145 EUROPE: TISSUE PROCESSING SYSTEMS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 146 ASIA PACIFIC: TISSUE PROCESSING SYSTEMS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 147 LATIN AMERICA: TISSUE PROCESSING SYSTEMS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 148 MIDDLE EAST: TISSUE PROCESSING SYSTEMS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 149 GCC COUNTRIES: TISSUE PROCESSING SYSTEMS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 150 SLIDE SCANNERS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 151 NORTH AMERICA: SLIDE SCANNERS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 152 EUROPE: SLIDE SCANNERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 153 ASIA PACIFIC: SLIDE SCANNERS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 154 LATIN AMERICA: SLIDE SCANNERS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 155 MIDDLE EAST: SLIDE SCANNERS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 156 GCC COUNTRIES: SLIDE SCANNERS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 157 OTHER EQUIPMENT MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 158 NORTH AMERICA: OTHER EQUIPMENT MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 159 EUROPE: OTHER EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 160 ASIA PACIFIC: OTHER EQUIPMENT MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 161 LATIN AMERICA: OTHER EQUIPMENT MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 162 MIDDLE EAST: OTHER EQUIPMENT MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 163 GCC COUNTRIES: OTHER EQUIPMENT MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 164 IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 165 IMMUNOHISTOCHEMISTRY KITS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 166 NORTH AMERICA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 167 EUROPE: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 168 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 169 LATIN AMERICA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 170 MIDDLE EAST: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 171 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 172 HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY REGION,
2022–2029 (USD MILLION)
TABLE 173 NORTH AMERICA: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 174 EUROPE: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 175 ASIA PACIFIC: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 176 LATIN AMERICA: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 177 MIDDLE EAST: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 178 GCC COUNTRIES: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 179 ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY REGION,
2022–2029 (USD MILLION)
TABLE 180 NORTH AMERICA: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 181 EUROPE: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 182 ASIA PACIFIC: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 183 LATIN AMERICA: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 184 MIDDLE EAST: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 185 GCC COUNTRIES: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 186 IMMUNOHISTOCHEMISTRY SOFTWARE MARKET, BY REGION,
2022–2029 (USD MILLION)
TABLE 187 NORTH AMERICA: IMMUNOHISTOCHEMISTRY SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 188 EUROPE: IMMUNOHISTOCHEMISTRY SOFTWARE MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 189 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 190 LATIN AMERICA: IMMUNOHISTOCHEMISTRY SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 191 MIDDLE EAST: IMMUNOHISTOCHEMISTRY SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 192 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 193 IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 194 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 195 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 196 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 197 EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 198 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 199 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 200 MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 201 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 202 COMMON CANCER MARKERS FOR IMMUNOHISTOCHEMICAL DIAGNOSIS
TABLE 203 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER,
BY REGION, 2022–2029 (USD MILLION)
TABLE 204 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 205 EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 206 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 207 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 208 MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 209 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 210 COMMON INFECTIOUS DISEASE MARKERS/ANTIGENS FOR IMMUNOHISTOCHEMICAL DIAGNOSIS
TABLE 211 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR
INFECTIOUS DISEASES, BY REGION, 2022–2029 (USD MILLION)
TABLE 212 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 213 EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 214 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 215 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 216 MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 217 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 218 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY REGION, 2022–2029 (USD MILLION)
TABLE 219 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 220 EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 221 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 222 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 223 MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 224 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 225 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2022–2029 (USD MILLION)
TABLE 226 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 227 EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 228 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 229 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 230 MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 231 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 232 COMMON IMMUNOHISTOCHEMISTRY MARKERS FOR NEUROLOGICAL DISEASES
TABLE 233 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2022–2029 (USD MILLION)
TABLE 234 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 235 EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 236 ASIA PACIFIC: I IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 237 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 238 MIDDLE EAST IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 239 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 240 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR
OTHER DISEASES, BY REGION, 2022–2029 (USD MILLION)
TABLE 241 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 242 EUROPE IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 243 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 244 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 245 MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 246 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 247 IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 248 IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 249 NORTH AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 250 EUROPE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 251 ASIA PACIFIC IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 252 LATIN AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 253 MIDDLE EAST: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 254 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 255 IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT AND TESTING, BY REGION, 2022–2029 (USD MILLION)
TABLE 256 NORTH AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT AND TESTING, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 257 EUROPE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT AND TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 258 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT AND TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 259 LATIN AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT AND TESTING, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 260 MIDDLE EAST: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT AND TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 261 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT AND TESTING, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 262 IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR
OTHER RESEARCH APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 263 NORTH AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 264 EUROPE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 265 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 266 LATIN AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 267 MIDDLE EAST: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 268 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 269 IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET, BY REGION,
2022–2029 (USD MILLION)
TABLE 270 NORTH AMERICA: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 271 EUROPE: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 272 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 273 LATIN AMERICA: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 274 MIDDLE EAST: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 275 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 276 IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 277 IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY REGION, 2022–2029 (USD MILLION)
TABLE 278 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS
AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 279 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS AND
DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 280 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 281 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 282 MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 283 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 284 IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 285 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 286 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 287 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 288 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 289 MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 290 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 291 IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY REGION,
2022–2029 (USD MILLION)
TABLE 292 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 293 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 294 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 295 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 296 MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 297 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 298 IMMUNOHISTOCHEMISTRY MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 299 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 300 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,
2022–2029 (USD MILLION)
TABLE 301 NORTH AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 302 NORTH AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION)
TABLE 303 NORTH AMERICA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 304 NORTH AMERICA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 305 NORTH AMERICA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 306 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2022–2029 (USD MILLION)
TABLE 307 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 308 NORTH AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 309 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2022–2029 (USD MILLION)
TABLE 310 NORTH AMERICA: KEY MACROINDICATORS
TABLE 311 US: RECENT DEVELOPMENTS IN IMMUNOHISTOCHEMISTRY MARKET
TABLE 312 US: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,
2022–2029 (USD MILLION)
TABLE 313 US: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 314 US: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,
2022–2029 (USD MILLION)
TABLE 315 US: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 316 US: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 317 US: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,
2022–2029 (USD MILLION)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 INCLUSIONS AND EXCLUSIONS
1.4 STUDY SCOPE
1.4.1 SEGMENTS COVERED
1.4.2 YEARS CONSIDERED
1.4.3 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 RESEARCH DESIGN
2.1.2 SECONDARY DATA
2.1.2.1 Secondary data sources
2.1.2.2 Objectives of secondary research
2.1.3 PRIMARY DATA
2.1.3.1 Objectives of primary research
2.2 MARKET SIZE ESTIMATION
2.2.1 REVENUE SHARE ANALYSIS (TOP-DOWN APPROACH)
2.2.2 INSIGHTS FROM PRIMARIES
2.3 MARKET GROWTH FORECAST
2.4 DATA TRIANGULATION
2.5 STUDY ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 IMMUNOHISTOCHEMISTRY MARKET OVERVIEW
4.2 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION AND
COUNTRY (2023)
4.3 IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2024 VS. 2029 (USD MILLION)
4.4 IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2023
4.5 IMMUNOHISTOCHEMISTRY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing prevalence of cancer and rising geriatric population
5.2.1.2 Technological innovations and advancements in immunohistochemistry diagnostics
5.2.1.3 Favorable reimbursement coverage for immunohistochemistry tests
5.2.1.4 Growing focus on digital pathology
5.2.2 RESTRAINTS
5.2.2.1 Adoption of alternative technologies in molecular diagnostics and research
5.2.2.2 Highly consolidated market
5.2.3 OPPORTUNITIES
5.2.3.1 Growing demand for precision/personalized medicines
5.2.3.2 Increasing adoption of companion diagnostics
5.2.3.3 Growth opportunities in emerging economies
5.2.3.4 Integration of AI in immunohistochemistry
5.2.4 CHALLENGES
5.2.4.1 Stringent regulatory requirements for tissue diagnostic instruments and consumables
5.2.4.2 Lack of standardization
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE OF IMMUNOHISTOCHEMISTRY PRODUCTS, 2023
5.4.2 INDICATIVE SELLING PRICE TREND FOR IMMUNOHISTOCHEMISTRY PRODUCTS, 2021–2023
5.4.3 INDICATIVE SELLING PRICE TREND FOR IMMUNOHISTOCHEMISTRY PRODUCTS, BY REGION, 2021–2023
5.5 TECHNOLOGY ANALYSIS
5.5.1 KEY TECHNOLOGIES
5.5.1.1 Automated immunohistochemistry systems
5.5.1.2 Multiplex immunohistochemistry
5.5.2 COMPLEMENTARY TECHNOLOGIES
5.5.2.1 Chromogenic detection
5.5.2.2 Fluorescent detection
5.5.3 ADJACENT TECHNOLOGIES
5.5.3.1 In situ hybridization
5.6 PATENT ANALYSIS
5.6.1 METHODOLOGY
5.6.2 INNOVATION AND PATENT APPLICATIONS
5.6.3 TOP PATENT APPLICANTS
5.7 VALUE CHAIN ANALYSIS
5.7.1 RESEARCH & DEVELOPMENT
5.7.2 MANUFACTURING
5.7.3 LOGISTICS AND POST-SALES
5.8 SUPPLY CHAIN ANALYSIS
5.9 ECOSYSTEM ANALYSIS
5.9.1 ROLE OF RAW MATERIAL SUPPLIERS
5.9.2 ROLE OF PRODUCT PROVIDERS
5.9.3 ROLE OF END USERS
5.9.4 ROLE OF REGULATORY AUTHORITIES
5.10 PORTER’S FIVE FORCES ANALYSIS
5.10.1 INTENSITY OF COMPETITIVE RIVALRY
5.10.2 BARGAINING POWER OF SUPPLIERS
5.10.3 BARGAINING POWER OF BUYERS
5.10.4 THREAT OF SUBSTITUTES
5.10.5 THREAT OF NEW ENTRANTS
5.11 KEY STAKEHOLDERS AND BUYING CRITERIA
5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.11.2 KEY BUYING CRITERIA
5.12 REGULATORY LANDSCAPE
5.12.1 REGULATORY ANALYSIS
5.12.1.1 North America
5.12.1.1.1 US
5.12.1.1.2 Canada
5.12.1.2 Europe
5.12.1.3 Asia Pacific
5.12.1.3.1 Japan
5.12.1.3.2 China
5.12.1.3.3 India
5.12.1.4 Latin America
5.12.1.4.1 Brazil
5.13 KEY CONFERENCES AND EVENTS, 2024–2025
5.14 INVESTMENT AND FUNDING SCENARIO
5.15 IMPACT OF AI/GEN AI ON IMMUNOHISTOCHEMISTRY MARKET
6 IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING
6.1 INTRODUCTION
6.2 ANTIBODIES
6.2.1 IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE
6.2.2 PRIMARY ANTIBODIES
6.2.2.1 Increasing adoption of targeted immunotherapy to drive segment
6.2.3 SECONDARY ANTIBODIES
6.2.3.1 Better signal amplification and easier manufacturing process to fuel segment growth
6.2.4 IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY
6.2.5 MONOCLONAL ANTIBODIES
6.2.5.1 Increased applications in cancer diagnostics to support market growth
6.2.6 POLYCLONAL ANTIBODIES
6.2.6.1 Better sensitivity and higher resistant to changes in antigen conformation to augment segment growth
6.3 REAGENTS
6.3.1 HISTOLOGICAL STAINS
6.3.1.1 Growing focus on cancer diagnostics and developmental research to drive segment
6.3.2 BLOCKING SERA AND REAGENTS
6.3.2.1 Need to prevent non-specific binding and provide accurate outcomes to drive adoption
6.3.3 CHROMOGENIC SUBSTRATES
6.3.3.1 Rapid detection and faster diagnosis to propel segment growth
6.3.4 FIXATION REAGENTS
6.3.4.1 Increased focus on retaining tissue morphology and antigenicity of target molecules to support adoption
6.3.5 DILUENTS
6.3.5.1 Focus on reducing non-specific background staining during immunostaining to aid segment growth
6.3.6 ORGANIC SOLVENTS
6.3.6.1 Need to prevent physical damage in specimens and improve clarity in tissue sample visualization to drive market
6.3.7 PROTEOLYTIC ENZYMES
6.3.7.1 Proteolytic enzymes to improve accessibility of target antibodies
6.3.8 OTHER REAGENTS
6.4 EQUIPMENT
6.4.1 SLIDE-STAINING SYSTEMS
6.4.1.1 Availability of technologically advanced slide-staining systems to fuel segment growth
6.4.2 TISSUE PROCESSING SYSTEMS
6.4.2.1 High equipment cost and need for extensive regulatory compliance to limit market
6.4.3 SLIDE SCANNERS
6.4.3.1 Accurate insights into complexity of tissue interactions and multi-parameter cellular expressions to aid adoption
6.4.4 OTHER EQUIPMENT
6.5 KITS
6.5.1 HUMAN IMMUNOHISTOCHEMISTRY KITS
6.5.1.1 Increasing focus on cancer research to fuel segment growth
6.5.2 ANIMAL IMMUNOHISTOCHEMISTRY KITS
6.5.2.1 Rising focus on drug safety and efficacy in preclinical drug testing to boost segment growth
6.6 SOFTWARE
6.6.1 GROWING FOCUS ON DIGITAL PATHOLOGY FOR MORE ACCURATE DIAGNOSIS TO DRIVE MARKET
7 IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION
7.1 INTRODUCTION
7.2 DIAGNOSTIC APPLICATIONS
7.2.1 CANCER
7.2.1.1 Increasing target population and rising adoption of targeted therapies to propel market growth
7.2.2 INFECTIOUS DISEASES
7.2.2.1 High prevalence of infectious diseases and need for early diagnosis to aid market growth
7.2.3 NEPHROLOGICAL DISEASES
7.2.3.1 Rising prevalence of renal transplant-associated conditions to drive market
7.2.4 AUTOIMMUNE DISEASES
7.2.4.1 Focus on differentiating autoimmune diseases from similar clinical presentations to augment market growth
7.2.5 NEUROLOGICAL DISEASES
7.2.5.1 Increasing global burden of neurological disorders to spur market growth
7.2.6 OTHER DISEASES
7.3 RESEARCH APPLICATIONS
7.3.1 DRUG DEVELOPMENT AND TESTING
7.3.1.1 Need for accurate and objective outcomes in drug testing to augment segment growth
7.3.2 OTHER RESEARCH APPLICATIONS
7.4 FORENSIC APPLICATIONS
7.4.1 INCREASED DEMAND FOR EFFECTIVE DETERMINATION OF PATHOLOGICAL CHANGES TO SUPPORT MARKET GROWTH
8 IMMUNOHISTOCHEMISTRY MARKET, BY END USER
8.1 INTRODUCTION
8.2 HOSPITALS AND DIAGNOSTIC LABORATORIES
8.2.1 LOW COST OF SPECIALTY DIAGNOSTIC TESTS AND HIGH DEMAND FOR PERSONALIZED MEDICINES TO AID MARKET GROWTH
8.3 ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS
8.3.1 GROWING APPLICATION OF IMMUNOHISTOCHEMISTRY TESTS FOR DRUG DEVELOPMENT TO POSITIVELY IMPACT MARKET GROWTH
8.4 OTHER END USERS
9 IMMUNOHISTOCHEMISTRY MARKET, BY REGION
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
9.2.2 US
9.2.2.1 US to dominate North American immunohistochemistry market during forecast period
9.2.3 CANADA
9.2.3.1 High incidence of cancer and increased demand for advanced diagnostics to propel market growth
9.3 EUROPE
9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
9.3.2 GERMANY
9.3.2.1 High investments in life science R&D and favorable reimbursement policies to drive market
9.3.3 UK
9.3.3.1 Rising prevalence of cancer and increasing government funding in health research to augment market growth
9.3.4 FRANCE
9.3.4.1 Increased research in cancer diagnosis and treatment to support market growth
9.3.5 ITALY
9.3.5.1 Advanced health infrastructure and high geriatric population to
fuel market growth
9.3.6 SPAIN
9.3.6.1 Increased demand for personalized medicines to boost adoption
of immunohistochemistry products
9.3.7 REST OF EUROPE
9.4 ASIA PACIFIC
9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
9.4.2 CHINA
9.4.2.1 Increasing focus on advanced cancer diagnostics to spur market growth
9.4.3 JAPAN
9.4.3.1 High geriatric population and increased government healthcare expenditure to support market growth
9.4.4 INDIA
9.4.4.1 Need for high-end pathology and diagnostic services to propel market growth
9.4.5 AUSTRALIA
9.4.5.1 Increased patient population and high demand for quality healthcare to aid market growth
9.4.6 SOUTH KOREA
9.4.6.1 Focus on precision healthcare and personalized medicines to
drive market
9.4.7 REST OF ASIA PACIFIC
9.5 LATIN AMERICA
9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
9.5.2 BRAZIL
9.5.2.1 Increasing incidence of chronic lifestyle diseases and rising investments by private companies to fuel market growth
9.5.3 MEXICO
9.5.3.1 Increasing research initiatives and rising cancer cases to drive market
9.5.4 REST OF LATIN AMERICA
9.6 MIDDLE EAST
9.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
9.6.2 GCC COUNTRIES
9.6.2.1 Saudi Arabia
9.6.2.1.1 Growing cancer burden and increasing focus on research to augment market growth
9.6.2.2 UAE
9.6.2.2.1 Favorable government initiatives and high investments in healthcare infrastructure to fuel market growth
9.6.2.3 Rest of GCC Countries
9.6.3 REST OF MIDDLE EAST
9.7 AFRICA
9.7.1 RAPID RISE IN CANCER CASES AND HIGH HEALTHCARE INVESTMENTS TO DRIVE MARKET
9.7.2 MACROECONOMIC OUTLOOK FOR AFRICA
10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.2 KEY PLAYER STRATEGY/RIGHT TO WIN
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN IMMUNOHISTOCHEMISTRY MARKET
10.3 REVENUE ANALYSIS, 2021–2023
10.4 MARKET SHARE ANALYSIS, 2023
10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
10.5.1 STARS
10.5.2 EMERGING LEADERS
10.5.3 PERVASIVE PLAYERS
10.5.4 PARTICIPANTS
10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
10.5.5.1 Company footprint
10.5.5.2 Offering footprint
10.5.5.3 Application footprint
10.5.5.4 Region footprint
10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
10.6.1 PROGRESSIVE COMPANIES
10.6.2 RESPONSIVE COMPANIES
10.6.3 DYNAMIC COMPANIES
10.6.4 STARTING BLOCKS
10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
10.7 COMPANY VALUATION AND FINANCIAL METRICS
10.7.1 FINANCIAL METRICS
10.7.2 COMPANY VALUATION
10.8 BRAND/PRODUCT COMPARISON
10.9 COMPETITIVE SCENARIO
10.9.1 PRODUCT LAUNCHES AND APPROVALS
10.9.2 DEALS
10.9.3 EXPANSIONS
10.9.4 OTHER DEVELOPMENTS
11 COMPANY PROFILES
11.1 KEY PLAYERS
11.1.1 F. HOFFMANN-LA ROCHE LTD.
11.1.1.1 Business overview
11.1.1.2 Products/Solutions offered
11.1.1.3 Recent developments
11.1.1.3.1 Product launches and approvals
11.1.1.3.2 Deals
11.1.1.4 MnM view
11.1.1.4.1 Key strengths
11.1.1.4.2 Strategic choices
11.1.1.4.3 Weaknesses and competitive threats
11.1.2 DANAHER CORPORATION
11.1.2.1 Business overview
11.1.2.2 Products/Solutions offered
11.1.2.3 Recent developments
11.1.2.3.1 Product launches and approvals
11.1.2.3.2 Deals
11.1.2.4 MnM view
11.1.2.4.1 Key strengths
11.1.2.4.2 Strategic choices
11.1.2.4.3 Weaknesses and competitive threats
11.1.3 AGILENT TECHNOLOGIES, INC.
11.1.3.1 Business overview
11.1.3.2 Products/Solutions offered
11.1.3.3 Recent developments
11.1.3.3.1 Product launches and approvals
11.1.3.3.2 Deals
11.1.3.3.3 Expansions
11.1.3.4 MnM view
11.1.3.4.1 Key strengths
11.1.3.4.2 Strategic choices
11.1.3.4.3 Weaknesses and competitive threats
11.1.4 PHC HOLDINGS CORPORATION
11.1.4.1 Business overview
11.1.4.2 Products/Solutions offered
11.1.4.3 Recent developments
11.1.4.3.1 Deals
11.1.4.3.2 Other developments
11.1.4.4 MnM view
11.1.4.4.1 Key strengths
11.1.4.4.2 Strategic choices
11.1.4.4.3 Weaknesses and competitive threats
11.1.5 THERMO FISHER SCIENTIFIC INC.
11.1.5.1 Business overview
11.1.5.2 Products/Solutions offered
11.1.6 MERCK KGAA
11.1.6.1 Business overview
11.1.6.2 Products/Solutions offered
11.1.7 BIO-RAD LABORATORIES, INC.
11.1.7.1 Business overview
11.1.7.2 Products/Solutions offered
11.1.8 BIO-TECHNE
11.1.8.1 Business overview
11.1.8.2 Products/Solutions offered
11.1.8.3 Recent developments
11.1.8.3.1 Deals
11.1.8.3.2 Expansions
11.1.8.3.3 Other developments
11.1.9 BECTON, DICKINSON AND COMPANY
11.1.9.1 Business overview
11.1.9.2 Products/Solutions offered
11.1.9.3 Recent developments
11.1.9.3.1 Expansions
11.1.10 TAKARA BIO INC.
11.1.10.1 Business overview
11.1.10.2 Products/Solutions offered
11.1.11 ENZO BIOCHEM INC.
11.1.11.1 Business overview
11.1.11.2 Products/Solutions offered
11.1.11.3 Recent developments
11.1.11.3.1 Expansions
11.1.12 SINO BIOLOGICAL, INC.
11.1.12.1 Business overview
11.1.12.2 Products/Solutions offered
11.1.12.3 Recent developments
11.1.12.3.1 Expansions
11.1.13 SAKURA FINETEK JAPAN CO., LTD.
11.1.13.1 Business overview
11.1.13.2 Products/Solutions offered
11.1.13.3 Recent developments
11.1.13.3.1 Product launches
11.1.13.3.2 Deals
11.1.14 CELL SIGNALING TECHNOLOGY, INC.
11.1.14.1 Business overview
11.1.14.2 Products/Solutions offered
11.1.14.3 Recent developments
11.1.14.3.1 Deals
11.1.15 BIO SB
11.1.15.1 Business overview
11.1.15.2 Products/Solutions offered
11.1.15.3 Recent developments
11.1.15.3.1 Product launches
11.1.16 MILTENYI BIOTEC
11.1.16.1 Business overview
11.1.16.2 Products/Solutions offered
11.1.17 ORIGENE TECHNOLOGIES, INC.
11.1.17.1 Business overview
11.1.17.2 Products/Solutions offered
11.2 OTHER PLAYERS
11.2.1 EAGLEBIO
11.2.2 BIOCARE MEDICAL, LLC
11.2.3 ELABSCIENCE BIONOVATION INC.
11.2.4 BIOGENEX
11.2.5 DIAGNOSTIC BIOSYSTEMS INC.
11.2.6 HISTO-LINE LABORATORIES
11.2.7 ROCKLAND IMMUNOCHEMICALS, INC.
11.2.8 CANDOR BIOSCIENCE GMBH
11.2.9 GENEMED BIOTECHNOLOGIES, INC.
12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 CUSTOMIZATION OPTIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
TABLE 1 IMMUNOHISTOCHEMISTRY MARKET: INCLUSIONS AND EXCLUSIONS
TABLE 2 IMMUNOHISTOCHEMISTRY MARKET: IMPACT ANALYSIS
TABLE 3 ESTIMATED NUMBER OF NEW CASES, BY REGION, 2022–2045 (THOUSAND)
TABLE 4 ESTIMATED PERCENTAGE INCREASE IN GERIATRIC POPULATION,
BY REGION, 2022–2050
TABLE 5 CPT CODES FOR IMMUNOHISTOCHEMISTRY PROCEDURES
TABLE 6 MAJOR ACQUISITIONS IN IMMUNOHISTOCHEMISTRY MARKET, 2020–2023
TABLE 7 AVERAGE SELLING PRICE FOR IMMUNOHISTOCHEMISTRY PRODUCTS, 2023
TABLE 8 INDICATIVE SELLING PRICE TREND FOR IMMUNOHISTOCHEMISTRY PRODUCTS, 2021–2023 (USD)
TABLE 9 INDICATIVE SELLING PRICE TREND FOR IMMUNOHISTOCHEMISTRY PRODUCTS,
BY REGION, 2021–2023 (USD)
TABLE 10 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2014–2024
TABLE 11 TOP 20 PATENT OWNERS IN IMMUNOHISTOCHEMISTRY MARKET, 2014–2024
TABLE 12 INDICATIVE LIST OF PATENTS IN IMMUNOHISTOCHEMISTRY MARKET, 2022–2024
TABLE 13 IMMUNOHISTOCHEMISTRY MARKET: ROLE OF RAW MATERIAL SUPPLIERS
TABLE 14 IMMUNOHISTOCHEMISTRY MARKET: ROLE OF PRODUCT PROVIDERS
TABLE 15 IMMUNOHISTOCHEMISTRY MARKET: ROLE OF END USERS
TABLE 16 IMMUNOHISTOCHEMISTRY MARKET: ROLE OF REGULATORY AUTHORITIES
TABLE 17 IMMUNOHISTOCHEMISTRY MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 18 BUYING CRITERIA FOR IMMUNOHISTOCHEMISTRY PRODUCTS, BY END USER
TABLE 19 US: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES
TABLE 20 EUROPE: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES
TABLE 21 JAPAN: CLASSIFICATION OF IN VITRO DIAGNOSTIC REAGENTS
TABLE 22 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
TABLE 23 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
TABLE 24 IMMUNOHISTOCHEMISTRY MARKET: DETAILED LIST OF KEY CONFERENCES
AND EVENTS, JANUARY 2024–DECEMBER 2025
TABLE 25 IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 26 IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGION,
2022–2029 (USD MILLION)
TABLE 27 NORTH AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 28 EUROPE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 29 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 30 LATIN AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 31 MIDDLE EAST: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 32 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 33 IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 34 PRIMARY ANTIBODIES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 35 NORTH AMERICA: PRIMARY ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 36 EUROPE: PRIMARY ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 37 ASIA PACIFIC: PRIMARY ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 38 LATIN AMERICA: PRIMARY ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 39 MIDDLE EAST: PRIMARY ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 40 GCC COUNTRIES: PRIMARY ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 41 SECONDARY ANTIBODIES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 42 NORTH AMERICA: SECONDARY ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 43 EUROPE: SECONDARY ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 44 ASIA PACIFIC: SECONDARY ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 45 LATIN AMERICA: SECONDARY ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 46 MIDDLE EAST: SECONDARY ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 47 GCC COUNTRIES: SECONDARY ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 48 IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,
2022–2029 (USD MILLION)
TABLE 49 MONOCLONAL ANTIBODIES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 50 NORTH AMERICA: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 51 EUROPE: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 52 ASIA PACIFIC: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 53 LATIN AMERICA: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 54 MIDDLE EAST: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 55 GCC COUNTRIES: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 56 POLYCLONAL ANTIBODIES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 57 NORTH AMERICA: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 58 EUROPE: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 59 ASIA PACIFIC: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 60 LATIN AMERICA: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 61 MIDDLE EAST: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 62 GCC COUNTRIES: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 63 IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 64 IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY REGION,
2022–2029 (USD MILLION)
TABLE 65 NORTH AMERICA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 66 EUROPE: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 67 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 68 LATIN AMERICA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 69 MIDDLE EAST: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 70 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 71 HISTOLOGICAL STAINS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 72 NORTH AMERICA: HISTOLOGICAL STAINS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 73 EUROPE: HISTOLOGICAL STAINS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 74 ASIA PACIFIC: HISTOLOGICAL STAINS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 75 LATIN AMERICA: HISTOLOGICAL STAINS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 76 MIDDLE EAST: HISTOLOGICAL STAINS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 77 GCC COUNTRIES: HISTOLOGICAL STAINS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 78 BLOCKING SERA AND REAGENTS MARKET, BY REGION,
2022–2029 (USD MILLION)
TABLE 79 NORTH AMERICA: BLOCKING SERA AND REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 80 EUROPE: BLOCKING SERA AND REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 81 ASIA PACIFIC: BLOCKING SERA AND REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 82 LATIN AMERICA: BLOCKING SERA AND REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 83 MIDDLE EAST: BLOCKING SERA AND REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 84 GCC COUNTRIES: BLOCKING SERA AND REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 85 CHROMOGENIC SUBSTRATES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 86 NORTH AMERICA: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 87 EUROPE: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 88 ASIA PACIFIC: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 89 LATIN AMERICA: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 90 MIDDLE EAST: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 91 GCC COUNTRIES: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 92 FIXATION REAGENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 93 NORTH AMERICA: FIXATION REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 94 EUROPE: FIXATION REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 95 ASIA PACIFIC: FIXATION REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 96 LATIN AMERICA: FIXATION REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 97 MIDDLE EAST: FIXATION REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 98 GCC COUNTRIES: FIXATION REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 99 DILUENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 100 NORTH AMERICA: DILUENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 101 EUROPE: DILUENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 102 ASIA PACIFIC: DILUENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 103 LATIN AMERICA: DILUENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 104 MIDDLE EAST: DILUENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 105 GCC COUNTRIES: DILUENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 106 ORGANIC SOLVENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 107 NORTH AMERICA: ORGANIC SOLVENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 108 EUROPE: ORGANIC SOLVENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 109 ASIA PACIFIC: ORGANIC SOLVENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 110 LATIN AMERICA: ORGANIC SOLVENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 111 MIDDLE EAST: ORGANIC SOLVENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 112 GCC COUNTRIES: ORGANIC SOLVENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 113 PROTEOLYTIC ENZYMES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 114 NORTH AMERICA: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 115 EUROPE: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 116 ASIA PACIFIC: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 117 LATIN AMERICA: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 118 MIDDLE EAST: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 119 GCC COUNTRIES: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 120 OTHER REAGENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 121 NORTH AMERICA: OTHER REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 122 EUROPE: OTHER REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 123 ASIA PACIFIC: OTHER REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 124 LATIN AMERICA: OTHER REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 125 MIDDLE EAST: OTHER REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 126 GCC COUNTRIES: OTHER REAGENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 127 IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 128 IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY REGION,
2022–2029 (USD MILLION)
TABLE 129 NORTH AMERICA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 130 EUROPE: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 131 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 132 LATIN AMERICA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 133 MIDDLE EAST: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 134 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 135 IMMUNOHISTOCHEMISTRY SLIDE-STAINING SYSTEMS MARKET, BY VOLUME, 2022–2029 (UNITS)
TABLE 136 SLIDE-STAINING SYSTEMS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 137 NORTH AMERICA: SLIDE-STAINING SYSTEMS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 138 EUROPE: SLIDE-STAINING SYSTEMS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 139 ASIA PACIFIC: SLIDE-STAINING SYSTEMS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 140 LATIN AMERICA: SLIDE-STAINING SYSTEMS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 141 MIDDLE EAST: SLIDE-STAINING SYSTEMS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 142 GCC COUNTRIES: SLIDE-STAINING SYSTEMS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 143 TISSUE PROCESSING SYSTEMS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 144 NORTH AMERICA: TISSUE PROCESSING SYSTEMS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 145 EUROPE: TISSUE PROCESSING SYSTEMS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 146 ASIA PACIFIC: TISSUE PROCESSING SYSTEMS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 147 LATIN AMERICA: TISSUE PROCESSING SYSTEMS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 148 MIDDLE EAST: TISSUE PROCESSING SYSTEMS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 149 GCC COUNTRIES: TISSUE PROCESSING SYSTEMS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 150 SLIDE SCANNERS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 151 NORTH AMERICA: SLIDE SCANNERS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 152 EUROPE: SLIDE SCANNERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 153 ASIA PACIFIC: SLIDE SCANNERS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 154 LATIN AMERICA: SLIDE SCANNERS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 155 MIDDLE EAST: SLIDE SCANNERS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 156 GCC COUNTRIES: SLIDE SCANNERS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 157 OTHER EQUIPMENT MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 158 NORTH AMERICA: OTHER EQUIPMENT MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 159 EUROPE: OTHER EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 160 ASIA PACIFIC: OTHER EQUIPMENT MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 161 LATIN AMERICA: OTHER EQUIPMENT MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 162 MIDDLE EAST: OTHER EQUIPMENT MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 163 GCC COUNTRIES: OTHER EQUIPMENT MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 164 IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 165 IMMUNOHISTOCHEMISTRY KITS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 166 NORTH AMERICA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 167 EUROPE: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 168 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 169 LATIN AMERICA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 170 MIDDLE EAST: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 171 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 172 HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY REGION,
2022–2029 (USD MILLION)
TABLE 173 NORTH AMERICA: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 174 EUROPE: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 175 ASIA PACIFIC: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 176 LATIN AMERICA: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 177 MIDDLE EAST: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 178 GCC COUNTRIES: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 179 ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY REGION,
2022–2029 (USD MILLION)
TABLE 180 NORTH AMERICA: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 181 EUROPE: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 182 ASIA PACIFIC: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 183 LATIN AMERICA: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 184 MIDDLE EAST: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 185 GCC COUNTRIES: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 186 IMMUNOHISTOCHEMISTRY SOFTWARE MARKET, BY REGION,
2022–2029 (USD MILLION)
TABLE 187 NORTH AMERICA: IMMUNOHISTOCHEMISTRY SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 188 EUROPE: IMMUNOHISTOCHEMISTRY SOFTWARE MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 189 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 190 LATIN AMERICA: IMMUNOHISTOCHEMISTRY SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 191 MIDDLE EAST: IMMUNOHISTOCHEMISTRY SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 192 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 193 IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 194 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 195 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 196 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 197 EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 198 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 199 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 200 MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 201 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 202 COMMON CANCER MARKERS FOR IMMUNOHISTOCHEMICAL DIAGNOSIS
TABLE 203 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER,
BY REGION, 2022–2029 (USD MILLION)
TABLE 204 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 205 EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 206 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 207 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 208 MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 209 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 210 COMMON INFECTIOUS DISEASE MARKERS/ANTIGENS FOR IMMUNOHISTOCHEMICAL DIAGNOSIS
TABLE 211 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR
INFECTIOUS DISEASES, BY REGION, 2022–2029 (USD MILLION)
TABLE 212 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 213 EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 214 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 215 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 216 MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 217 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 218 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY REGION, 2022–2029 (USD MILLION)
TABLE 219 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 220 EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 221 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 222 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 223 MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 224 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 225 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2022–2029 (USD MILLION)
TABLE 226 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 227 EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 228 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 229 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 230 MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 231 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 232 COMMON IMMUNOHISTOCHEMISTRY MARKERS FOR NEUROLOGICAL DISEASES
TABLE 233 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2022–2029 (USD MILLION)
TABLE 234 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 235 EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 236 ASIA PACIFIC: I IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 237 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 238 MIDDLE EAST IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 239 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 240 IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR
OTHER DISEASES, BY REGION, 2022–2029 (USD MILLION)
TABLE 241 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 242 EUROPE IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 243 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 244 LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 245 MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 246 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 247 IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 248 IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 249 NORTH AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 250 EUROPE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 251 ASIA PACIFIC IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 252 LATIN AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 253 MIDDLE EAST: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 254 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 255 IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT AND TESTING, BY REGION, 2022–2029 (USD MILLION)
TABLE 256 NORTH AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT AND TESTING, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 257 EUROPE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT AND TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 258 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT AND TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 259 LATIN AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT AND TESTING, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 260 MIDDLE EAST: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT AND TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 261 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT AND TESTING, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 262 IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR
OTHER RESEARCH APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 263 NORTH AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 264 EUROPE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 265 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 266 LATIN AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 267 MIDDLE EAST: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 268 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 269 IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET, BY REGION,
2022–2029 (USD MILLION)
TABLE 270 NORTH AMERICA: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 271 EUROPE: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 272 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 273 LATIN AMERICA: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 274 MIDDLE EAST: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 275 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 276 IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 277 IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY REGION, 2022–2029 (USD MILLION)
TABLE 278 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS
AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 279 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS AND
DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 280 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 281 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 282 MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 283 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 284 IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 285 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 286 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 287 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 288 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 289 MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 290 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 291 IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY REGION,
2022–2029 (USD MILLION)
TABLE 292 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 293 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 294 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 295 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 296 MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 297 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS,
BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 298 IMMUNOHISTOCHEMISTRY MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 299 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY,
2022–2029 (USD MILLION)
TABLE 300 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,
2022–2029 (USD MILLION)
TABLE 301 NORTH AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 302 NORTH AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION)
TABLE 303 NORTH AMERICA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 304 NORTH AMERICA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 305 NORTH AMERICA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 306 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2022–2029 (USD MILLION)
TABLE 307 NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 308 NORTH AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 309 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2022–2029 (USD MILLION)
TABLE 310 NORTH AMERICA: KEY MACROINDICATORS
TABLE 311 US: RECENT DEVELOPMENTS IN IMMUNOHISTOCHEMISTRY MARKET
TABLE 312 US: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,
2022–2029 (USD MILLION)
TABLE 313 US: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 314 US: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,
2022–2029 (USD MILLION)
TABLE 315 US: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 316 US: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION)
TABLE 317 US: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,
2022–2029 (USD MILLION)
